Adverum Biotechnologies, Inc. (NASDAQ:ADVM) is set to announce second quarter earning results on Monday 10th August 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, ADVM to report 2Q20 loss of $ 0.28 per share from revenue of $ 0.09 million.
For the full year, analysts anticipate top line of $ 0.30 million, while looking forward to loss of $ 1.18 per share bottom line.
Previous Quarter Performance
Adverum Biotechnologies, Inc. unfold loss for the first quarter of $ 0.31 per share, from the revenue of . The quarterly revenues compared with the same quarter last year. The consensus estimates are loss of $ 0.27 per share from $ 0.09 million in revenue. The bottom line results missed street analysts by $ 0.04 or 14.81 percent, at the same time, top line results analysts by $ 4.28 million or .
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Stock Performance
According to the previous trading day, closing price of ADVM was $ 18.46, representing a 272.18 % increase from the 52 week low of $ 4.96 and a 31.58 % decrease over the 52 week high of $ 26.98.
The company has a market capital of $ 1.48 billion and is part of the Healthcare sector and Biotechnology industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”ADVM” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Conference Call
Adverum Biotechnologies, Inc. will be hosting a conference call at 4:30 PM eastern time on 10th August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.adverum.com
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, engages in developing gene therapy product candidates to treat ocular and rare diseases. Its pipeline of product candidates includes ADVM-022, an adeno- associated virus (AAV). 7m8-aflibercept for the treatment of wet age-related macular degeneration; ADVM-043, an investigational gene therapy candidate for the treatment of alpha-1 antitrypsin deficiency; and ADVM-053, a preclinical gene therapy product candidate for the treatment of hereditary angioedema.
